ReadYourDNA

Cytarabine (Cytosar-U)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Cytarabine

What it is

Cytarabine (Ara-C) is a chemotherapy medicine of the antimetabolite group: inside cells it becomes a false building block that stops DNA from being copied. It is a backbone of treatment for acute myeloid leukaemia and is also used for acute lymphoblastic leukaemia and some lymphomas. It is sold as Cytosar-U, among other names.

How genes come into it

Studies have looked at genes along cytarabine's path: the carrier that takes it into cells (SLC29A1), the enzymes that activate it (DCK, CMPK1), the enzyme that inactivates it (CDA), and ribonucleotide reductase (RRM1, RRM2). Some CDA variants have been linked to more side effects or to a weaker effect. The findings come from single or a few studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Cytarabine. Upload your DNA file to see which of these rows apply to you.

Rated evidence (33 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

CDA rs2072671: Level 3. Toxicity: Leukemia, Lymphoma. 7.

CDA rs3215400: Level 3. Toxicity. 6.

CDA rs532545: Level 3. Efficacy: Leukemia, Myeloid, Acute, Neoplasms. 4.

CDA rs532545: Level 3. Toxicity: Leukemia, Myeloid. 4.

Response (25 findings)

Studies of how well it worked in people carrying a variant.

ADH1A rs1826909: Allele T is associated with increased resistance to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.

ADH1A rs6811453: Allele A is associated with increased resistance to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele G.

DCK rs2306744: Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.

DCK rs80143932: Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.

Side effects (1 finding)

Studies of side effects in people carrying a variant.

CDA rs2072671: Genotype CC is associated with decreased clearance of cytarabine in children Lymphoma, T-Cell.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

5-FU (Antimetabolites)

Alimta (Antimetabolites)

Fludara (Antimetabolites)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com